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Sphingolipid metabolism is deeply regulated along the differentiation and development of the central nervous system (CNS),
and the expression of a peculiar spatially and temporarily regulated sphingolipid pattern is essential for the maintenance of the
functional integrity of the nervous system. Microglia are resident macrophages of the CNS involved in general maintenance of
neural environment. Modulations in microglia phenotypes may contribute to pathogenic forms of inflammation. Since defects
in macrophage/microglia activity contribute to neurodegenerative diseases, it will be essential to systematically identify the
components of the microglial cell response that contribute to disease progression. In such complex processes, the sphingolipid
systems have recently emerged to play important roles, thus appearing as a key new player in CNS disorders. This review provides
a rationale for harnessing the sphingolipid metabolic pathway as a potential target against neuroinflammation.
1. An Introduction to Sphingolipids
During the last decades, sphingolipids have come to the
fore for their involvement in signalling events that control
a variety of cellular activities [1]. All sphingolipids are
composed by a long-chain sphingoid base backbone (e.g.,
sphingosine), an amide-linked long-chain fatty acid and
one of various polar head groups, that defines the various
classes of sphingolipid subtypes, such as a hydroxyl group
in ceramide, phosphorylcholine in sphingomyelin (SM), and
carbohydrates in glycosphingolipids (GLSs). Sphingolipids
are mainly present at the level of the membranes, of which
they contribute to define physical and chemical properties.
Some of the intermediate molecules of the sphingolipids
metabolism (ceramide, sphingosine-1-phosphate (S1P), glu-
cosylceramide and (GluCer), gangliosides) and their generat-
ing and modifying enzymes (neutral and acid sphingomyeli-
nase (A-SMase), acid ceramidase, sphingosine kinase (SK),
GluCer synthase, glycosyltransferases, 𝛽-galactosidase, and
𝛽-hexosaminidase) contribute to regulate cellular growth,
differentiation, and apoptosis [2–6]. Sphingolipids have com-
plex metabolic pathways that lead to the transformation of
many sphingolipids in other sphingolipids and vice versa
most often acting in concert to fine tune biological responses.
In this respect, a relevant system is the so-called “sphin-
golipid rheostat,” that is, the relative amounts of ceramide,
sphingosine, and S1P. Ceramide can be synthesised either
de novo by the sequential action of serine palmitoyltrans-
ferase, (dihydro) ceramide synthase, and (dihydro) ceramide
desaturase at the cytoplasmic leaflet of the membrane of the
endoplasmic reticulum [7] or through the breakdown of SM
by the activation of the catabolic enzymes sphingomyelinases.
This occurs in the endolysosomal compartment [8], at the
outer and inner leaflets of the plasma membrane [9–12] and
through the newly discovered salvage pathway, consisting in
the breakdown of complex sphingolipids into sphingosine
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and reacylation to produce ceramide [13]. Sphingosine can
also be phosphorylated by SK1 and SK2 to produce S1P.
Whereas ceramide is proapoptotic and inhibits autophagy,
S1P enhances cell survival [14–16]. The “sphingolipid rheo-
stat” has thus been proposed as one of the mechanisms that
control the cell fate towards either apoptosis or survival. This
regulatory action occurs within and contributes to the overall
regulation of the inflammatory status as well as the vascular
and cardiac functions [17].
A complex aspect of the “sphingolipid rheostat” is that
ceramide can be converted to other sphingolipids with
signalling properties. The level of intracellular ceramide
is indeed controlled by its transformation in GluCer by
the microsomal enzyme, UDP-glucose: ceramide d-glucosyl-
transferase also known as GluCer synthase, a transmembrane
protein localised in the cis/medial Golgi. GluCer is involved
in many cellular processes such as cell proliferation, dif-
ferentiation, oncogenic transformation, and tumour metas-
tasis, and more recently, it has been implicated in venous
thrombosis and in the anticoagulant activity of protein C
[18]. Moreover, GluCer contributes to the physical properties
and physiological functions of membranes and serves as the
precursor for hundreds of species of GLSs found in different
mammalian cell types.
Among them relevant are gangliosides GLSs contain-
ing sialic acid synthesised starting from GluCer, lacto-
sylceramide, and galactosylceramide. Biosynthesis of these
complex sphingolipids consists in the sequential addition
of carbohydrate moieties to the existing acceptor glycolipid
molecule and is catalysed by a series of specific glycosyltrans-
ferases localised in the Golgi apparatus [19]. The localisation
of gangliosides in the outer leaflets of plasma membrane
explains why they are involved in cell-cell recognition, adhe-
sion, and signal transduction and are components of cell
surface lipid rafts alongside proteins, SM, and cholesterol [5,
20–22]. A schematic representation of sphingolipidmetabolic
pathway is depicted in Figure 1.
Sphingolipid metabolism is deeply regulated along the
differentiation and development of the central nervous sys-
tem (CNS), and the expression of a peculiar spatially and
temporarily regulated sphingolipid pattern is essential for the
maintenance of the functional integrity of the nervous system
[23–27].
2. Neuroinflammation and CNS
Resident Macrophages
There is a general agreement that neuroinflammation in
nervous system disorders has active role in pathophysiology
onset and progression, in conditions ranging from chronic
pain and epilepsy to neurodegenerative diseases such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), lysoso-
mal storage diseases, and amyotrophic lateral sclerosis and
may even contribute to schizophrenia, depression, and other
psychiatric disorders [28–30].
Many studies have focussed on the role of microglia
in neuroinflammation and neurodegenerative diseases [31–
35]. Indeed, in contrast to neurones and other glial cells,
microglia are of haematopoietic origin and constitute the
immune cells of the brain responding to pathogen infections
and injuries. Microglial cells are specialised macrophages
of the CNS distinct from other glial cells, such as astro-
cytes and oligodendrocytes, because of their origin, mor-
phology, gene expression pattern, and functions [36–38].
They express macrophage-associated markers indicating a
particularly close relationshipwith bonemarrow-derived and
thioglycollate-elicited peritoneal macrophages [38]. Indeed
recent results in mice suggest that microglia originate from
yolk sac macrophages that migrate into the CNS during early
embryogenesis and are independent from cells that arise
by definitive haematopoiesis in the bone marrow and from
circulating cells [38].
Microglial cells are involved in phagocytosis and general
maintenance of neural environment. Although these cells are
quiescent under normal conditions, they are rapidly activated
in response to pathological stimuli. On activation, resting
microglia change their morphology immunophenotype and
expression pattern of inflammatory mediators, leading to
immune and inflammatory responses [35, 38–41]. In par-
ticular, activated microglial cells produce proinflammatory
mediators, including cytokines, chemokines, reactive oxygen
species (ROS), and nitric oxide (NO), which contribute
to the clearance of pathogen infections. If prolonged or
excessive, microglial cell activationmay result in pathological
forms of inflammation that contribute to the progression
of neurodegenerative and neoplastic diseases [28, 38, 42].
Mechanisms that regulate the transition of microglia from
the activated state associated with acute inflammation to
phenotypes associated with tissue repair, and ultimately to
phenotypes associated with normal CNS homeostasis, are
poorly understood.
Although it is still difficult to define conditions under
which microglial cells are “good” or “bad,” strategies to
counter the harmful effects of macrophage/microglial acti-
vation are studied widely to improve and enhance poten-
tial treatment strategies for disease conditions linked to
neuroinflammation [28, 38, 43, 44]. In this respect, much
current research has focussed on the signalling pathways
that regulate inflammatory mediator production and subset
macrophage development [38, 45]. Studies are still needed
however to fully understand the role of these cells within
the contexts of normal homeostasis and acute or chronic
neuroinflammatory diseases [38, 45].
3. Sphingolipid Systems and Inflammation in
CNS Diseases
The brain is one of the richest organs in lipid content; hence
changes in the lipid levels may cause pathogenic processes.
Publications from late 1980s and early 1990s suggested that
decreased brain lipid levels and alterations in brain lipid
metabolism are connected with AD. At present, there is
a general consensus that, among CNS lipids, sphingolipid
metabolism has a key neuropathological impact and sph-
ingolipids have begun to be investigated in major CNS
diseases [23, 24], including those related to inflammatory
states [24, 25, 29]. In this respect, experimental evidence
points to an important role for sphingolipids in inflammation







































Figure 1: Schematic representation of main sphingolipid metabolic pathway. SM: sphingomyelin; Cer: ceramide; A-SMase: acid
sphingomyelinase; N-SMase: neutral sphingomyelinase; A-CDase: acid ceramidase; N-CDase: neutral ceramidase; SMS: sphingomyelin
synthase; Sph: sphingosine; S1P: sphingosine-1-phosphate; SK: sphingosine kinase; dhCer: dihydroceramide; CerS: ceramide synthase;
GluCer: glucosylceramide; GCS: glucosylceramide synthase; GT: glycosyltransferase; GSL: ganglioside; Ser: serine.
[46, 47].The contribution of sphingolipid metabolism to dis-
ease progression has received considerable attention because
of increased levels of ceramide in the CNS under AD [29],
X-adrenoleukodystrophy, and multiple sclerosis [48] and the
demonstration of the ceramide role in induction of neural cell
death [48, 49], proinflammatory gene expression [50, 51], and
oxidative stress [48, 49, 51]. Overall, in CNS sphingolipids
may be involved in regulating key intracellular events of
cytokine signalling, in the production of the proinflamma-
tory molecules eicosanoids [35], and in modulating cellular
mechanisms as relevant as apoptosis, astroglial activation and
astrogliosis, increase of T-cell migration, and activation of
several receptor-mediated pathways [23, 25, 52, 53].
3.1. Alzheimer’s Disease. There is evidence indicating that the
increased brain-ceramide levels in AD lead not only to
neuronal dysfunctions [54] but may also promote inflam-
matory processes [55]. The neuropathologic characteristics
of AD are amyloid plaques (aggregates of amyloid-𝛽 pep-
tides) and neurofibrillary tangles (formed by accumulation
of hyperphosphorylated tau protein), which firstly affect
the medial, temporal, and parietal lobes and part of the
frontal cortex of the brain [56]. In primary oligodendrocyte
cultures derived from neonatal rat brains A𝛽 peptide seems
to activate SM hydrolysis causing ceramide accumulation
[55]. Interestingly, ceramide influences the stabilisation of the
enzyme 𝛽-secretase (BACE1), responsible for the cleavage of
the amyloid precursor protein (APP) to form A𝛽 peptide
[57] in human neuroglioma cells. The accumulation of A𝛽
peptide is responsible for the activation of microglia with
subsequent release of large amounts of proinflammatory
cytokines and ROS, contributing to the neuroinflammation
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and neurodegeneration [58]. Recent works on BV2 cells, a
murine microglial cell line which is a suitable model for in
vitro study of microglia, hypothesized that the inflammatory
response of microglia in AD brains is mediated via S1P [59].
Recently, Tamboli and coworkers [60] have demonstrated a
very interesting link between the storage of sphingolipids
and the pathogenesis of AD, starting from the evidence
that the presence of autophagosomes in dystrophic neurites
is common to brains from patients affected by AD. The
authors indicate that the accumulation of sphingolipids plays
a dual role in autophagy; while promoting the induction
of autophagy, sphingolipid may also impair the turnover
of autophagic vesicles, leading to their accumulation and
consequently to the accumulation of APP.
3.2. Lysosomal Storage Disease Family. Other ceramide met-
abolites, that is, GLSs, are known to cause neurodegenerative
and neuroinflammatory diseases, such as Gaucher, Fabry,
mucopolysaccharidosis I and IIIA, and gangliosidosis [24,
29, 61]. Gangliosidosis is a GLS lysosomal storage disease
in which the storage lipid is a GLS containing one or more
sialic acid residue. It includes theGM2 storage disorders, Tay-
Sachs and Sandhoff disease, and the GM1 storage disorders.
Mouse models of the GM2 and GM1 gangliosidosis have
been studied to determine whether there is a common
neuroinflammatory component to these disorders. Of inter-
est, Sandhoff disease mice treated with nonsteroidal anti-
inflammatory drugs (indomethacin, aspirin, and ibuprofen)
and antioxidants (L-ascorbic acid and-tocopherol acetate)
lived significantly longer than untreated littermates and
showed a slower rate of disease progression, thus suggest-
ing that inflammation may play an important role in the
pathogenesis of gangliosidosis [62]. In this respect, bothGM2
and GM1 gangliosidosis mouse models exhibit progressive
inflammatory reactions in the CNS which are characterized
by altered blood brain barrier, apoptosis, and microglial acti-
vation with consequent release of proinflammatory cytokine
[63]. It has been hypothesized that the microglial activation
observed in these pathologies occurs via the Toll-like receptor
4 and that gangliosides may be involved in this process [39,
64].
3.3. Parkinson’s and Huntington’s Diseases. Targeting sphin-
golipid metabolism may also represent today an underex-
ploited yet realistic opportunity to design novel therapeutic
strategies for the intervention in PD. Indeed, it has been
reported that the treatment with the monosialoganglioside
GM1 restores at least partially neurochemical, pharmaco-
logical, histological, and behavioural parameters in different
animal models of PD; it also reverses the dopaminergic
deficits in nigrostriatal neurons of aged rats [27].
Several early studies suggested that altered sphingolipid
metabolism is associated with Huntington’s disease (HD)
[27]. Noteworthy, a disrupted pattern of glycolipids (acidic
and neutral lipids) and/or ganglioside levels was reported
in both the forebrain of the R6/1 transgenic mice (a mouse
model of HD) and caudate samples from humanHD subjects
[65]. However, although R6/1 transgenic mice have severe
cerebellar GLS abnormalities that may account, in part, for
their abnormal motor behaviour, the same abnormalities
were not found in the cerebellum of human HD subjects
[66]. The potential benefits of using gangliosides for treating
the behavioural deficits associated with HD have also been
described [67]. In particular, the administration of GM1
restores ganglioside levels in HD cells and promotes activa-
tion of the protein kinase Akt and phosphorylation of mutant
huntingtin (htt) gene, leading to decreasedmutant htt toxicity
and increased survival of HD cells [68]. More recently, in vivo
experiments demonstrated that intraventricular infusion of
ganglioside GM1 induces phosphorylation of mutant htt at
specific serine amino acid residues leading to attenuated htt
toxicity and restores motor function in already symptomatic
HD mice [69].
4. Sphingolipid Systems and
Macrophages/Microglia Inflammatory
Responses
Implications for sphingolipids as signalling molecules for
inflammatory responses come from various contexts [46, 47,
70]. Of interest, as comprehensively reviewed byNixon [47], a
significant body of research now indicates that sphingolipids
are intimately involved in the inflammatory process and that
these lipids, together with associated enzymes and recep-
tors, can provide effective drug targets for the treatment of
pathological inflammation. In some cell types sphingolipids
can have specific effects that are integral to regulation of
the inflammatory response. Sphingolipids themselves may,
in certain circumstances, initiate parts of the inflammatory
process [47]. However, at present, controversial reports have
been presented on the beneficial versus detrimental role
of sphingolipids and in particular ceramides in inflamma-
tion. Some studies have shown the proinflammatory role
of ceramides in pulmonary oedema, airway inflammation,
cystic fibrosis, and inflammatory bowel disease [71–76],
whereas others have reported the anti-inflammatory effects of
ceramides in macrophages, neutrophils, and corneal epithe-
lial cells [74, 77–79].
As suggested before, modulation in macrophage/micro-
glia phenotypes may contribute to pathogenic forms of
inflammation and neurodegenerative diseases. Among sph-
ingolipids, short-chain ceramides, commonly used to mimic
the mechanisms of action of naturally occurring long-
chain ceramides, have been demonstrated to have an anti-
inflammatory effect in rodent macrophages. In particular, C2
to C8 short-chain ceramides reduce inflammation in cells
stimulated by lipopolysaccharide (LPS), a bacterial polysac-
charide commonly used as a proinflammatory stimulus. This
anti-inflammatory effect was induced in part through the
inhibition of cytokine, such as tumour necrosis factor (TNF-
𝛼), and chemokines, such as macrophage inflammatory
protein 2, levels [78] and in part through the reduction of
inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-
2) expression with consequent decrease of ROS level. These
actions are accompanied by inhibition of several protein
kinases, such as I𝜅B kinase, p38 mitogen-activated protein
kinase (MAPK), and protein kinase C [80, 81]. Ceramide
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inhibits TNF-𝛼 secretion by regulating TNF𝛼-converting
enzyme activity [79] in mouse primary macrophages. More-
over, A-SMase knock-out mice showed an upregulation of
serum TNF-𝛼 in response to LPS [82]. Noteworthy, C2
to C8 short-chain ceramides reduce inflammation in LPS-
stimulated rodent microglia (BV2 cells and primary cul-
tures), interfering with the binding of LPS to its cell surface
receptors (i.e., TLR-4) and modulating intracellular pro-
/anti-inflammatory signalling molecules [74]. In particular,
C2 ceramide exerts its anti-inflammatory function also by
reducing inflammation induced by TLR-2 or TLR-3 agonists
and the phosphorylation of three types of kinases (MAPKs,
Akt, and JAK) [74].
The possibility that long-chain ceramides mediate a
proinflammatory effect in macrophages has been also
demonstrated, thus suggesting that the function of ceramides
differs depending on acyl chain length and cell types
[6, 52, 74]. For instance, TNF-𝛼 activation of A-SMase
results in the production of long-chain ceramides, C16–
C24, with the subsequent activation of the proinflammatory
transcription factor, nuclear factor-𝜅B (NF-𝜅B) [83]. NF-
𝜅B is a family of ubiquitous transcription factors inducing
more than 150 genes in different mammalian cells, includ-
ing macrophages/microglia. Of interest, many of NF-𝜅B-
dependent genes encode cytokines and chemokines, such as
interleukin-1𝛽 (IL-1𝛽), IL-6, IL-8, and monocyte chemoat-
tractant protein-1, in addition to proinflammatory enzymes,
such as COX-2, all of which have important roles in inflam-
mation [47].
A well-defined downstream effector of ceramide is S1P,
and also this sphingolipid participates in inflammatory
signalling cascades [84]. Besides recruiting lymphocytes to
blood and lymph, S1P may promote immune competent
cell survival and proliferation but also interferes with their
activation [47]. LPS activate the SK1/S1P signalling axis in
several cell types including mouse macrophages [85] leading
to translocation of SK1 to the plasma membrane where it
converts its substrate sphingosine to S1P. It is important to
note that in activatedmicroglia SK1 expression is upregulated
[59]. In general S1P elicits a wide variety of cellular responses
including inflammation and can act intracellularly as a
second messenger or extracellularly by binding to the G
protein-coupled receptors S1P1 to S1P5 [86, 87]. The BV2
microglial cells and purified microglia from mouse primary
cultures have been shown to express all or some of the five
S1P receptors [59, 88]. Of interest, the reported role of S1P
in cell proliferation, migration, and changes in morphology
of rat astrocytes and microglia suggest a crucial role of S1P
in neuroinflammatory disease conditions [89]. Moreover,
it has been shown that the suppression of SK1 activity in
activated mouse microglia inhibited the expression levels
of TNF-𝛼, IL-1𝛽, and iNOS and release of TNF-𝛼 and
NO [59]. The addition of exogenous S1P to activated cells
enhanced microglia inflammatory responses, suggesting that
S1P acts as an upstream factor to induce the production of
proinflammatory cytokines and neurotoxic substances (such
as NO). Similarly to what occurs in peripheral immune cells
[90], these data suggest that the SK1/S1P pathway is involved
in the inflammatory response of activated microglia in an
autocrine/paracrine signalling fashion in which the secreted
S1P can regulate the release of proinflammatory factors by
microglia.
Also gangliosides are capable of activating glia, thereby
leading to inflammatory responses in the brain [39]. In
particular, in rat brain microglia and astrocytes exposure to
gangliosides can induce the production of various inflam-
matory mediators, such as cytokines and iNOS [39, 91–93].
This gangliosides function is mediated through the activation
of different inflammation-associated signalling molecules,
includingNF-𝜅B, JAK, STAT (signal transducer and activator
of transcription), and MAPK [39, 91, 93–95]. These results
suggest that ceramide may contribute to inflammatory sig-
nalling cascades in microglia through different derivatives
other than S1P.
5. Conclusion
The inflammatory function ofmicroglia represents a rich field
of investigation for the understanding of neuropathophysi-
ological processes. While it is important to remember that
many of neuroimmune actions of microglia are beneficial,
as well as necessary for a healthy CNS, research has been
particularly focussed on detrimental effects of neuroin-
flammation in association with CNS diseases. Defects in
macrophage/microglia activity may contribute to pathogenic
forms of inflammation and neurodegenerative diseases; it
will thus be essential to systematically identify the mech-
anisms of cell modulation in different neuroinflamma-
tory/neurodegenerative disease states and the components
of the microglial cell response that contribute to disease
progression. The data summarised in this review clarify
that various sphingolipid systems play important roles in
CNS disorders. The information discussed in this review
makes us aware that much remains to be learned about
sphingolipid-dependent signalling mechanisms that regulate
neuroinflammation and that targeting sphingolipid pathways
may prove to be a useful therapeutic strategy capable of
affecting a diverse array of CNS disorders. Resolving this
issue, especially in response to specific microglia activity-
dependent mechanisms, will be an area of future focus that
deserves attention also in therapeutic perspective.
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